Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target of $5.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Tenaya Therapeutics’ promising advancements in their gene therapy pipeline. The company is making significant progress in its AAV-based gene therapy and precision medicine candidates, particularly focusing on cardiovascular applications. Their financial position is also stable, with $88.2 million in cash, which is expected to support operations through the second half of 2026.
Tenaya’s ongoing clinical trials, such as TN-201 for MYBPC3-HCM and TN-401 for PKP2-associated ARVC, are on track with promising timelines for data release. The RIDGE study, which complements the TN-401 development, has provided valuable insights and is progressing well with over 175 patients enrolled. These developments suggest a strong potential for Tenaya’s therapies to address unmet medical needs, supporting Pantginis’s optimistic outlook on the stock.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $40.00 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.